Also known as: BC
Breast cancer is a malignant tumor that starts in breast tissue and is now the most commonly diagnosed cancer in women globally. Outcomes vary substantially by stage at diagnosis and access to timely treatment.
IceCure Medical's ProSense cryoablation system gains IRB approval for the ChoICE post-marketing study in low-risk breast cancer, with patient enrollment expected soon. Additionally, Thomas Hospital in Alabama becomes the first facility in the state to install ProSense, with procedures starting this month.
A study in The Oncologist found that Oncotype DX testing improved overall survival in ultra-low-risk HR+ breast cancer patients, with chemotherapy further prolonging survival in high-risk cases. Genomic testing supports personalized treatment decisions.
A first-in-human T-cell therapy showed lasting benefit in children with DIPG and relapsed CNS tumors, while a preclinical mRNA vaccine reduced neuroblastoma tumor size by 70%. Aneuploidy predicted response to olaparib plus irinotecan.
New research highlights strategies to overcome cancer drug resistance: a triple-drug AML combination, a breast cancer resistance target, evolutionary treatment switching, DNA damage mechanisms, and sildenafil's anti-metastatic potential.
Roche stock trades steadily as group sales reach the mid-CHF 60 billion range. Q1 2025 revenue edged higher, and 2025 guidance points to low to mid single digit sales growth.
Recent studies have uncovered new cancer therapeutic targets and strategies, including self-assembling antibody-drug conjugates, a dual-action metabolic drug, and a BRAF protein structure. Research also advanced on dendritic cell vaccines, the origins of a rare childhood leukemia, and cancer cachexia treatment.
A drug-free wearable device that generates low-intensity electric fields reduced tumor growth and spread in preclinical models of triple-negative breast cancer. The treatment appeared to boost immune activity around tumors and will be tested in an upcoming NIH-sponsored clinical trial.
Pilot genetic testing at ESMO Breast Cancer 2026 found inherited variants in 8.6% of breast and 10.1% of ovarian cancer survivors. A systematic review linked mammographic surveillance to a 50% lower mortality risk.
A digital mental health program significantly reduced anxiety in breast cancer survivors, with additional coaching helping depression, while a broader review finds eHealth tools improve psychological support in cancer care.
Relay Therapeutics reported Q4/FY 2025 results, outlined 2026 milestones for zovegalisib, and held ~$555M in cash. Initial vascular anomaly data and breast cancer triplet data are expected in 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780240 |
Axillary Web Syndrome After Breast Cancer Surgery: Incidence, Risk Factors, and Functional Outcomes |
RECRUITING | |
| NCT07779135 |
Effect of Aromatherapy on the Management of Chemotherapy-Induced Neuropathy (CIN) |
RECRUITING | |
| NCT07776964 |
Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) |
NOT_YET_RECRUITING | NA |
| NCT07776951 |
Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast Cancer Patients (PhActHealth Study) |
RECRUITING | NA |
| NCT07776613 |
A Study of Romosozumab in People With Breast Cancer and Osteoporosis |
RECRUITING | PHASE2 |
| NCT07776301 |
Application of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in Breast Cancer |
RECRUITING | NA |
| NCT07775014 |
Percutaneous Cryoablation for the Treatment of Breast Cancer |
NOT_YET_RECRUITING | NA |
| NCT07774624 |
Study of SKB103 in HER2-negative Breast Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07770243 |
AI-Based Symptom Management for Post-Treatment Breast Cancer Survivors |
NOT_YET_RECRUITING | NA |
| NCT07768436 |
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer |
RECRUITING | PHASE2 |
